China channel feed – Endpoints News

China channel feed

FDA inspection of China-based site making Coherus' potential new cancer drug ends with three observations

Last year

China's market regulator fines, confiscates revenue from pharmas for monopolizing APIs for epinephrine

Last year

C4 Therapeutics gets $35M from Betta Pharmaceuticals to develop and market NSCLC drug in China

Last year

XtalPi inks $250M pact with Lilly after Pfizer success

Last year

Innovent showcases topline PhII win for high-dose obesity drug in China

Last year

Roche hands Chinese biotech $70M for HER2 drug that can go to the brain

3 years ago

Eisai’s cancer drug Halaven at the center of $2B pact with BlissBio, like its Bristol Myers ADC deal

3 years ago

Chinese biotech startup adds $315M to the bank after bringing 5 Takeda drugs to its fold

3 years ago

Pyramid inks TROP2 pact with China biotech to follow suit of Gilead, AstraZeneca-Daiichi Sankyo

3 years ago

Pharmaron expanding Liverpool manufacturing facility with a $186M+ price tag

3 years ago

Brii Biosciences stops manufacturing Covid-19 antibody combo, plans to withdraw EUA request

3 years ago

F-star's sale to Chinese buyer cleared by CFIUS following months of holdup

3 years ago

Shanghai's Abbisko out-licenses EGFR candidate in potentially nine-figure deal

3 years ago

Scoop: Ascletis' NASH subsidiary scraps US PhII trial in favor of China

3 years ago

In push to expand its CAR-T therapies to US, China biotech Oricell raises additional $45M

3 years ago

Kinnate engineers $24M deal to win control of China joint venture back from OrbiMed, Foresite

3 years ago

Updated: Takeda bets $400M cash on colorectal cancer drug in boost to China's Hutchmed

3 years ago

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

3 years ago

Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies

3 years ago

Q&A: Can inhaled vaccines mount comeback for one-time leader in China's Covid race?

3 years ago

WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in billions lost from US unverified list

3 years ago

HighTide Therapeutics rides NASH R&D wave with a $107M raise

3 years ago

Scoop: Bing Yao’s ArriVent lining up $145M raise, after $150M debut in 2021

3 years ago

Updated: US puts hold on F-star's takeover by China’s Sino Biopharm, citing national security risks

3 years ago

First page Previous page 7 8 91011 12 13 Next page Last page